Consulta las presentaciones y los estudios destacados en ESMO 2026.
Presentaciones orales
23.10.2026, 16:15-17:45
538RO - Patient (pt)-reported outcomes (PROs) from the Phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC
Molécula / tratamiento
Giredestrant
Autoría
Gustavo Werutsky (Porto Alegre, Brazil)
Sesión / ubicación
Rapid oral session,Almeria Auditorium - Hall 9
24.10.2026, 10:12-11:45
2RO - Retrospective exploratory biomarker (BM) analyses from evERA Breast Cancer (BC): A Phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) in the post-CDK4/6 inhibitor (i) setting
Molécula / tratamiento
Giredestrant
Autoría
Sara M. Tolaney (Boston, United States of America)
Sesión / ubicación
Rapid oral 1: Breast cancer, advanced stage
Pósteres Roche
24.10.2026, 12:00-12:45
23P - Updated interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS Breast Cancer (BC): A Phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with oestrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC)
Molécula / tratamiento
Inavolisib, Gireddestrant
Autoría
Hope S. Rugo
Sesión / ubicación
Poster Area - Hall 5
24.10.2026, 12:00 - 12:45
BREnnA: Phase II/III randomised study of ZNA-1041 or tucatinib (TUC), in combination with trastuzumab + capecitabine (HX), in patients (pts) with HER2positive locally advanced or metastatic breast cancer (HER2+ LA/mBC) with or without central nervous system (CNS) metastases
Molécula / tratamiento
ZNA-1041
Autoría
Nancy U. Lin
Sesión / ubicación
Ubicación pendiente de confirmación
Estudios independientes financiados por Roche (IIS)
24.10.2026, 12:00 -12:45
1853P - First-Line Treatment Patterns and Outcomes in HR+/HER2− Advanced Breast Cancer After Recurrence Following Adjuvant Endocrine Therapy: GEICAM/2014-03 (RegistEM) Study
Molécula / tratamiento
1st L mBC HER2 RH+
Autoría
Ariadna Tibau, (Barcelona, Spain)
Sesión / ubicación
Poster Session Poster Area - Hall 5
24.10.2026, 12:00-12:45
594P - Real-world eligibility for DESTINY-Breast11 (DB-11) neoadjuvant escalation criteria and outcomes of DB-11-eligible vs DB-11- ineligible patients with HER2-positive early breast cancer (HER2+ eBC)
